title: Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
abstract: OBJECTIVE
  In a Phase I/II trial, we investigated concurrent weekly docetaxel and concomitant boost radiation in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) after induction chemotherapy.
  
  
  METHODS
  Patients presented with American Joint Committee on Cancer Stage III/IV and were treated initially with induction chemotherapy using cisplatinum/5-fluorouracil (PF), carboplatinum-5-FU, or docetaxel-PF. Patients then received docetaxel four times weekly with concomitant boost (CB) radiation (1.8 Gy once-daily X20, 1.8/1.5 Gy twice a day). Fifteen patients each received 20 mg/M2 and 25 mg/M2.
  
  
  RESULTS
  Thirty-one patients were enrolled and 30 were evaluable for response and toxicity. Median follow-up was 42 months (range, 27-63 months). Primary sites were: oropharynx 19, oral cavity 2, larynx/hypopharynx 5, and unknown primary 4. Eighty-seven percent of patients had N2/N3 disease; 60% had T3/T4 disease. Twenty percent of patients had a complete response (CR) to induction chemotherapy. After chemoradiotherapy, 21 of 30 patients had a CR, 2 had progressive disease, and 7 had partial response (PR). Nineteen of 26 patients presenting with neck disease had neck dissections, and 7 of 19 were positive. Ninety-three percent of all patients were rendered disease-free after all planned therapy. Treatment failed in 8 patients, and 7 have died of disease. An additional patient died with no evidence of disease. Twenty-one patients (70%) are currently alive with no evidence of disease. No acute dose-limiting toxicity was observed at either dose level.
  
  
  CONCLUSIONS
  This intensive treatment regimen of concurrent docetaxel/concomitant boost radiation and surgery after induction chemotherapy in poor prognosis patients yields good local regional control and survival. Docetaxel/CB chemoradiotherapy represents an aggressive alternative regimen to platinum-based chemoradiotherapy or surgery in patients who have a poor response to induction chemotherapy.
authors: Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA 02115, USA. roy_tishler@dfci.harvard.edu
authors: Roy B
authors: RB
authors: Tishler
authors: Marshall R
authors: MR
authors: Posner
authors: Charles M
authors: CM
authors: Norris
authors: Anand
authors: A
authors: Mahadevan
authors: Christopher
authors: C
authors: Sullivan
authors: Laura
authors: L
authors: Goguen
authors: Lori J
authors: LJ
authors: Wirth
authors: Rosemary
authors: R
authors: Costello
authors: MaryAnn
authors: M
authors: Case
authors: Sara
authors: S
authors: Stowell
authors: Dan
authors: D
authors: Sammartino
authors: Paul M
authors: PM
authors: Busse
authors: Robert I
authors: RI
authors: Haddad